Caris Life Sciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 73 to 86.

Caris Life Sciences, Inc. ( (CAI) ) has released its Q2 earnings. Here is a breakdown of the information Caris Life Sciences, Inc. presented to its investors.Elevate Your Investing Strategy: Take ...

Caris Life Sciences CEO and chairman David Dean Halbert, celebrates the company's initial public offering and listing on the Nasdaq exchange by ringing the opening bell on Wednesday, June 18, 2025.

IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the ...

Caris Life Sciences (CAI) stock is expected to make its trading debut on Wednesday after the company priced its IPO at $21/share. Read more here.

Irving-based Caris Life Sciences filed to go public on the Nasdaq and revealed a significant revenue jump between 2023 and 2024. Still, the company remains unprofitable and is grappling with a ...

Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million. The Irving, Texas ...

Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering Provided by PR Newswire May 23, 2025, 2:54:00 PM ...

The initial public offering price is expected to be between $16.00 and $18.00 per share. Caris has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol "CAI." ...

IRVING, Texas, June 9, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it ...